Innovative Approaches for Slowing Disease Progression in Parkinson’s Disease

Chairs: Kumar Budur, MD, MS; Ibrahim Turkoz, PhD; Ira Shoulson, MD; Mark Frasier, PhD

This is a one-day symposium hosted by ISCTM, in collaboration with Michael J Fox Foundation (MJFF).

Within the past decade, there has been a significant progress in our understanding of the pathophysiology in Parkinson’s disease.  With the identification of new targets, potential novel interventions and advances in the translational space, the focus has rapidly shifted from symptomatic treatments to disease modifying strategies in Parkinson’s disease.  Despite significant progress in the science, there has been little discussion and agreement on clinical trial design strategies, innovative statistical analyses, and regulatory approaches for disease modification treatments in Parkinson’s disease. 

This one-day symposium will include Parkinson’s disease pioneers and innovators from academia, industry, and regulatory agencies.  The objective is to building consensus through collaborative and constructive discussions on strategies and clinical trial design considerations for slowing the progression in Parkinson’s disease.  This is an exciting time for neurodegenerative diseases in general, and Parkinson’s disease in particular. This symposium is intended to advance the science and strategy of disease modification in Parkinson’s disease drug development, with the ultimate goal of bringing meaningful medicines to patients.